A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer

Alessandra Tognoni, L. Cadenotti, F. Pensa, F. Vaira, A. Vigani, L. Bancalari, S. Cordani, R. Maggiani, P. A. Canessa, P. Pronzato

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m 2 days 1-3, ifosfamide 1500 mg/m 2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m 2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.

Original languageEnglish
Pages (from-to)306-309
Number of pages4
JournalJournal of Chemotherapy
Volume11
Issue number4
Publication statusPublished - 1999

Fingerprint

Mesna
Ifosfamide
Granulocyte Colony-Stimulating Factor
Drug Combinations
Non-Small Cell Lung Carcinoma
Cisplatin
Outpatients
Filgrastim
vinorelbine

Keywords

  • Cisplatin
  • Dose intensity
  • Filgrastim
  • Ifosfamide
  • Lung cancer
  • Mesna
  • Non-small-cell lung cancer (NSCLC)
  • Vinorelbine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer. / Tognoni, Alessandra; Cadenotti, L.; Pensa, F.; Vaira, F.; Vigani, A.; Bancalari, L.; Cordani, S.; Maggiani, R.; Canessa, P. A.; Pronzato, P.

In: Journal of Chemotherapy, Vol. 11, No. 4, 1999, p. 306-309.

Research output: Contribution to journalArticle

Tognoni, A, Cadenotti, L, Pensa, F, Vaira, F, Vigani, A, Bancalari, L, Cordani, S, Maggiani, R, Canessa, PA & Pronzato, P 1999, 'A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer', Journal of Chemotherapy, vol. 11, no. 4, pp. 306-309.
Tognoni, Alessandra ; Cadenotti, L. ; Pensa, F. ; Vaira, F. ; Vigani, A. ; Bancalari, L. ; Cordani, S. ; Maggiani, R. ; Canessa, P. A. ; Pronzato, P. / A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer. In: Journal of Chemotherapy. 1999 ; Vol. 11, No. 4. pp. 306-309.
@article{acf35ab21edc43648498346d07626e68,
title = "A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer",
abstract = "Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m 2 days 1-3, ifosfamide 1500 mg/m 2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m 2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28{\%} was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.",
keywords = "Cisplatin, Dose intensity, Filgrastim, Ifosfamide, Lung cancer, Mesna, Non-small-cell lung cancer (NSCLC), Vinorelbine",
author = "Alessandra Tognoni and L. Cadenotti and F. Pensa and F. Vaira and A. Vigani and L. Bancalari and S. Cordani and R. Maggiani and Canessa, {P. A.} and P. Pronzato",
year = "1999",
language = "English",
volume = "11",
pages = "306--309",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "4",

}

TY - JOUR

T1 - A phase II study of a three-drug combination (cisplatin, ifosfamide and vinorelbine) plus granulocyte-colony stimulating factor in advanced non small cell lung cancer

AU - Tognoni, Alessandra

AU - Cadenotti, L.

AU - Pensa, F.

AU - Vaira, F.

AU - Vigani, A.

AU - Bancalari, L.

AU - Cordani, S.

AU - Maggiani, R.

AU - Canessa, P. A.

AU - Pronzato, P.

PY - 1999

Y1 - 1999

N2 - Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m 2 days 1-3, ifosfamide 1500 mg/m 2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m 2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.

AB - Twenty-nine patients with advanced non-small-cell lung cancer (NSCLC) were treated with a combination of cisplatin 20 mg/m 2 days 1-3, ifosfamide 1500 mg/m 2 days 1-2 (plus mesna as uroprotector) and vinorelbine 25 mg/m 2 days 1 and 5; filgrastim was given at the dose of 300 μg subcutaneously from day 8 to day 15. A response rate of 28% was observed. The activity of this combination in an outpatient setting, with acceptable toxicity, has been demonstrated.

KW - Cisplatin

KW - Dose intensity

KW - Filgrastim

KW - Ifosfamide

KW - Lung cancer

KW - Mesna

KW - Non-small-cell lung cancer (NSCLC)

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0032803130&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032803130&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 306

EP - 309

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - 4

ER -